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Background: Chromosomal microarray analysis (CMA) is currently the most widely adopted clinical test for
patients with unexplained intellectual disability (ID), developmental delay (DD), and congenital anomalies. Its
use has revealed the capacity to detect copy number variants (CNVs), as well as regions of homozygosity,
that, based on their distribution on chromosomes, indicate uniparental disomy or parental consanguinity that
is suggestive of an increased probability of recessive disease.
Results: We screened 149 Lebanese probands with ID/DD and 99 healthy controls using the Affymetrix Cyto
2.7 M and SNP6.0 arrays. We report all identified CNVs, which we divided into groups.
Pathogenic CNVs were identified in 12.1% of the patients. We review the genotype/phenotype correlation in
a patient with a 1q44 microdeletion and refine the minimal critical regions responsible for the 10q26 and 16q
monosomy syndromes.
Several likely causative CNVs were also detected, including new homozygous microdeletions (9p23p24.1,
10q25.2, and 8p23.1) in 3 patients born to consanguineous parents, involving potential candidate genes.
However, the clinical interpretation of several other CNVs remains uncertain, including a microdeletion
affecting ATRNL1. This CNV of unknown significance was inherited from the patient’s unaffected-mother; therefore,
additional ethnically matched controls must be screened to obtain enough evidence for classification of this CNV.
Conclusion: This study has provided supporting evidence that whole-genome analysis is a powerful method for
uncovering chromosomal imbalances, regardless of consanguinity in the parents of patients and despite the
challenge presented by analyzing some CNVs.
Keywords: Affymetrix 2.7 M, Affymetrix 6.0, Consanguinity, Copy number variants, Database, Intellectual
disability, Lebanese populationBackground
Intellectual disability (ID) is defined as a significant limi-
tation in both intellectual function and adaptive behavior
that originates before the age of 18 [1]. Its prevalence in
the general population is estimated to be between 1 and
3%, with higher disability rates in developing countries* Correspondence: megarbane@usj.edu.lb
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unless otherwise stated.[2-5]. In Lebanon, the latest statistical study on ID showed
a relatively high incidence (4.1%) [6].
The etiological factors of ID are heterogeneous. ID
with a genetic origin is more frequently found in patients
with an IQ < 50 (50%) than in other patients (15%), with
chromosomal aberrations being the most common causes
[7,8]. Screening for these imbalances is routinely per-
formed with conventional cytogenetic and molecular tests.
Nevertheless, the resolution is limited to 5 Mb in standard
karyotyping; thus, the detection of imbalances is success-
ful only in less than 4% of patients with ID (when trisomyal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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situ hybridization (FISH) and multiplex ligation dependent
probe amplification (MLPA), which allow the detection of
microimbalances smaller than 5 Mb in targeted regions,
can each explain 3% of the patients’ phenotypes [9,10].
With the introduction of the chromosomal microarray
analysis (CMA) technique, which is capable of detecting
submicroscopic rearrangements referred to as copy num-
ber variants (CNVs), as well as regions of homozygosity
(ROH), in search for uniparental disomy or consanguinity,
10-20% of patients with unexplained ID can now be pro-
vided with a molecular diagnosis [10,11].
Herein, we report the results of a large CMA analysis
project on a cohort of 149 patients with unexplained ID
and a cohort of 99 controls. Our findings underscore the
implication of clinically relevant CNVs in ID/DD and
emphasize the ability of the technique in detecting ROH
that are highly suggestive of an increased likelihood of
rare recessive diseases.
Results
In this cohort of 149 Lebanese patients having ID, DD,
with or without CA, we found an average of 6 chromo-
somal imbalances per proband of which 67.8% had previ-
ously been reported as benign. Of the remaining CNVs,
either previously reported or newly found, 10.9% were
microdeletions and 21.3% were microduplications.
Twenty causal alterations (group I, Table 1) were identi-
fied in 18 patients. Eight of these pathogenic CNVs were
terminal, whereas the other 12 were interstitial. One
aberration, a microdeletion of 2,262 kb in patient P15, was
originally determined to be a balanced translocation by
standard karyotyping. Eight (8/149 or 5.3%) were greater
than 5 Mb and, therefore, could have been detected by
conventional karyotyping. All CNVs belonging to group I
were of de novo origin, except for one that was inherited
from the father of patient P10 [12].
Six CNVs were classified in group IIa (Table 2A). In
5 of these, the de novo or inherited status could be
confirmed. Three of those CNVs were found in patients
with consanguineous parents. They were homozygous and
were segregated in the families. Other likely causative
CNVs are de novo and have morbid gene like GRHL2 and
RICTOR.
One CNV, belonging to group IIb and involving a
pathogenic gene, was inherited from a normal parent
and was therefore considered to be of unclear signifi-
cance (Table 2B).
Twenty other CNVs were classified as familial variants
(group IIc, Additional file 2: Table S1) that were most
likely benign. Eleven were microduplications that ranged
between 47 and 1,612 kb. One inherited microdeletion
from a healthy mother encompassed intron 4 of the
AUTS2 gene.Thirty-nine CNVs, above the limited threshold set for
the detection of true positive CNVs but with no parental
DNA available for further investigation, were also classi-
fied as variants of uncertain clinical significance (VOUS)
(group IId, Additional file 3: Table S2), of which 84.6%
(33/39) were microduplications.
The arrays were also analyzed for significant regions of
absence of heterozygosity in search for uniparental di-
somy, mosaicism, and autosomal recessive pathogenicity
in patients with consanguineous parents. Our results did
not suggest uniparental disomy or mosaicism but con-
firmed the high rate of consanguineous marriage in
Lebanon: 42 of the 149 patients (28.2%) were confirmed
as being born to closely related parents and had greater
than 66 Mb of ROH, which correlates with an estimate
of F = 1/32. Three of these patients had an ROH size
equivalent to that of the theoretical coefficient of in-
breeding, F = 1/4, ten patients had an estimated F = 1/8,
22 probands had F = 1/16, and 7 patients had F = 1/32
(Additional file 4: Table S3).
Discussion
Herein, we present our results from the first Lebanese
CMA study investigating the involvement of CNVs in
patients with ID/DD. We validated the Cyto2.7 M array
platform with a confirmation of 99 identified CNVs
using Quantitative PCR (Q-PCR). This resulted in the
determination of a clinical threshold of 62 kb with at
least 49 consecutive markers. Most abnormalities that
do not meet these requirements could not be confirmed
and their presence is due to the “cleanness” of the signal
detected from the array. This confirms results from pre-
vious studies mentioning the importance of taking into
consideration array Quality Control parameters [13].
However, the genomic content should be checked in all
CNVs as it points to candidate genes that could be
missed when applying any threshold. An improvement
of the reliability of small CNVs in newer arrays is then
required and was applied in the CytoScan HD array by
enriching the number and type of markers in a region
(oligonucleotide and SNP probes) [14].
Our results indicate an overall diagnostic yield of 12.1%,
a value in agreement with previous studies obtaining a de-
tection rate between 10% and 20% [10,15]. Different array
types from the same company, like Affymetrix 500 K SNP
array are used with a close threshold of 100 kb and also
obtain similar diagnostic yield [16]. We confirmed, once
more, the pathogenic effect of CNVs belonging to group I.
However, we found new genotype/phenotype correlations
in three patients, with 1q44, 10q26.11-q26.13, or 16q22.3
interstitial microdeletions, belonging to group I. We
reviewed reports of patients with aberrations that overlap
these CNVs and propose a variety of new findings for
these 3 aberrations.
Table 1 Goup I, abnormal CNVs overlapping known microdeletion or microduplication syndromes and/or known pathogenic genes
Patient Sex Locus Type
of CNV
Clinical features Region’s
minimal
size (Kb)
Minimal breakpoints (bp) Estimated
coefficient of
inbreeding (F)
Location
of the
imbalance
Inheritance
P1 M 1p36.33p36.22 Loss ID, DD, Cardiac malformations, bilateral inguinal hernias, omphalocele,
hearing loss, hypotrophic, triangular face, cleft lip and palate, agenesis
of the corpus callosum
6,750 130,110- 136,860,002 0 Terminal De novo
P2 F 1q44 Loss ID, DD, clonus before the age of 8 months, microcephaly, growth
retardation, short neck, low set ears, round face, a prominent and broad
forehead, frontal bossing, small bulbous nose, anteverted nostril, deep set
root, accentuated central depression lower lip, pointed chin, convergent
strabismus, and midface hypoplasia , prominent supraorbital ridges, deep
set eyes, dark infraorbital circles
4,293 242,895,230-247,189,052 0 Terminal De novo
6p22.3 Loss 20 15,569,409-15,589,866 Interstitial De novo
P3 M 2q22.3q23.1 Loss ID, DD, language impairment, scaphocephaly, microcephaly, autistic
features, melanotic spot on belly and thighs, enophthalmia,
undescended left testis, aggression
3,836 145,103,064- 148,939,789 0 Interstitial De novo
P4 M 4p16.2p15.33 Loss DD, strabismus, amblyopia, right thumb brachydactyly, missing lateral
incisors
4,700 5,406,881- 10,107,795 0 Interstitial De novo
P5 F 6q16.1q16.3 Loss DD, ID, obesity, macrocephaly, strabismus, kyphosis, hyperactive,
tapered fingers, genu valgum, short feet
9,622 95,014,210- 104,636,586 0 Interstitial De novo
P6 M 8q24.23q24.3 Gain DD, hypotonia, hernia diafragmatica 9,726 136,543,915- 146,270,808 1/32 Terminal De novo
P7 F 9p24.3p22.3 Loss ID, trigonocephaly, agenesis of the corpus callosum, polymicrogyria,
blepharophimosis, facial dysmorphism
14,694 42,900- 14,737,134 0 Interstitial De novo
P8 M 10q26.11q26.13 Loss DD, microcephaly, language impairment, undescended right testis,
micropenis, facial dysmorphism, exophthalmos, broad nasal bridge,
large ears, short and flat forehead, straight eyebrows
4,570 119,502,107- 124,072,142 0 Interstitial De novo
P9 F 12p12.1 Loss ID, scaphocephaly, strabismus, camptodactyly, polymicrogyria, frontal
bossing
4,260 23,572,642- 23,576,902 0 Interstitial De novo
P10 [12] F 12q24.23q24.31 Loss DD, retrognathism, constipation, obesity, epilepsy, flat face, Café au lait spots 980 119,633,574- 120,613,673 0 Interstitial Paternal
inheritance
P11 F 14q24.3q32.2 Loss Metatarsus adductus, enophthalmia, microretrognatism, hypotonia 23,028 75,432,536- 98,460,571 0 Interstitial De novo
P12 F 15q11.2q13.1 Loss DD, axial hypotonia, ataxia, abnormal white matter signal 5,038 21,170,573-26,208,862 0 Interstitial De novo
P13 F 16p13.3 Gain ID, short stature, renal artery stenosis, malformation of thumbs, club
foot
1,558 3,057,380-4,616,365 0 Terminal De novo
P14 M 16q11.2q21 Gain Ptosis, cardiac malformation, psychomotor retardation, ID 17,756 45,027,595-62,783,676 0 Interstitial De novo
P15 M t(1;16)(q25.3;q22.3) Loss 16q22.3 ID,DD, cerebral lesion sequelae, cleft palate 2,262 70,288,663-72,551,141 0 Interstitial De novo
P16 M 22q13.2q13.33 Loss DD, ID, hyperelastic skin of the abdomen, ligamentous laxity,
pachyonychia
7,896 41,678,984-49,575,139 0 Terminal De novo
P17 M t(15;19)(q26.3;p13.3) Loss 15q26.3 ID 992 99,225,025-100,217,472 0 Terminal De novo
Gain 19p13.3 3,124 196,466-3,321,442 Terminal
P18 M Xq28 Gain ID 249 153,211,216-153,461,068 0 Terminal De novo
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Table 2 Group IIa, rare variants likely pathogenic. Group IIb, variants of unclear significance. ND: not determined
Patient Sex Locus Type
of CNV
Copy
number
state
Clinical features Region’s
minimal
size (Kbp)
Minimal
breakpoints (bp)
Estimated
coefficient of
inbreeding (F)
Location
of the
imbalance
Inheritance Genes
A. Group IIa, rare variants likely pathogenic
Unknown CNVs
but putatively
pathogenic
P19 M 5p13.1 Loss 1 Ambiguous genitalia, microcephaly,
seizures, bone malformations, and early
death
19 39,113,442-39,132,945 0 Interstitial ND 3 kb of
RICTOR
P20 M 9p24.1p23 Loss 0 Trigonocephaly, gross motor and
language milestones delay, ID, a
dolichocephalic pattern skull, a mild
pachygyria of occipitoparietal lobes, and
a mild widening of the frontal
pericerebral subarachnoid space
720 8,517,597-9,238,069 1/16 Interstitial Inherited in an
autosomal
recessive manner
PTPRD
175 9,306,105-9,481,477
P21 F 8q22.3 Loss 0 Ataxia, hearing loss, ID 4 102,690,846- 102,695,425 0 Interstitial De novo GRHL2
(intronic)
21q22.11 Gain 3 67 32,547,099- 32,614,769 Interstitial De novo C21orf45
MRAP
URB1
P22 M 8p23.1 Loss 0 Syndactyly, cardiac malformation, DD,
ID, ptosis,
284 8,678,807- 8,963,498 1/4 Interstitial Inherited in an
autosomal
recessive manner
ERI1,
MFHAS1
P23 M 10q25.2 Loss 0 Psychomotor retardation, autistic
features, ID
157 114,038,460- 114,196,241 1/16 Interstitial Inherited in an
autosomal
recessive manner
ACSL5
ZDHHC6
TECTB
B. Group IIb, Variants of unclear significance
Morbid genes
inherited from a
healthy parent
P24 M 10q25.3 Loss 1 Autistic behaviour, syringomielia 64 116,960,967-117,025,746 1/16 Interstitial Maternal ATRNL1
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Patient P2, a 48-month-old female with ID, DD, and
facial dysmorphisms (Table 1), was found to have two de
novo microdeletions involving the 1q44ter region and
exon 5 of JARID2. The deletion of 1q44 is a recognizable
clinical disorder characterized by short stature, DD, ID,
microcephaly, facial dysmorphism, variable types of seiz-
ure, and partial to complete agenesis of the corpus callo-
sum (ACC) [17-19]. Moreover, deletions of JARID2 are
associated with cognitive impairment and facial features
such as prominent supraorbital ridges, deep set eyes,
dark infraorbital circles, and midface hypoplasia [20,21].
When carefully examined, patient P2 has the same facial
features noted in patients with both deletions, JARID2
deletion and the 1q44 syndrome.
Although the 1q44 syndrome forms a recognizable
phenotype, the disentangling of the genetic causes of seiz-
ure, ACC, and microcephaly has been challenging. To
explain these features, several critical regions in the 1q44
deletions were defined; the AKT3 gene has been proposed
to be responsible for microcephaly, and the ZNF238 gene
(also named ZBTB18) to have a potential role in ACC
[22,23]. In patient P2, neither of these genes was deleted;
however, she had microcephaly. Ballif et al. proposed a
critical region containing three genes: COX20 with no
known relevant function, HRNUPU and HRNUPU-AS1.
The last two when mutated, are thought to be responsible
for seizures with the occurrence of the first seizure not ex-
ceeding 4 years of age [22,24]. The deletion of HRNUPU,
which is involved in embryonic brain development, is
most likely pathogenic because of its haploinsufficiency.
Its antisense transcript, HRNUPU-AS1, has been found to
affect the expression of HRNUPU [25]. Our patient’s dele-
tion (Additional file 1: Figure S1) overlapped the critical
region defined by Ballif et al. encompassing the seizure-
causing genes proposed in the literature, although the pa-
tient had microcephaly but no seizures. Seizures may not
have yet started in the proband studied here, although
seizure onset occurs early in the described patients, mak-
ing future seizures very unlikely. The deletion may also
have incomplete penetrance or variable expressivity. Fi-
nally, a combination of the 1q44 deletion and the 20 kb
deletion of JARID2’s exon 5 might explain the patient’s
phenotype and an epistatic relationship may exist between
the copy number imbalances, exacerbating the proband’s
intellectual impairment and leading to the modification of
the patient’s clinical features.
10q26.11-q26.13 microdeletion
Patient P8 was found to have an interstitial 4,570 kb de
novo 10q26.11-q26.13 microdeletion. This deleted region
and those of some previously described patients with an
interstitial 10q26 do not include the minimal critical
region (MCR) previously described by Yatsenko et al.[26-32]; however they share similar clinical findings: ID,
growth and psychomotor retardation, and microcephaly.
We narrowed down the smallest region of overlap re-
sponsible for these common features to chr10:122,878,779-
124,072,142. This region contains 5 genes: NSMCE4A,
ATE1, TACC2, BTBD16, and FGFR2.
Genital anomalies have been also associated with the
deletion of the 10q25.3-q26.1 segment [26]. We suggest
the common region 10q26.12 to be responsible for these
defects and reduce the previously critical region to a
region including only WDR1 and PPAPDC1A (article
accepted in AMJG).16q22.3 microdeletion
The 16q22.3 microdeletion was found in patient P15,
who was known to have an apparently balanced trans-
location on standard karyotype between chromosome 1
and 16. Published reports of chromosome 16 microdele-
tions are very rare. Few cases involve the 16q22.3 region
deleted in patient P15 [33-40]. These patients show simi-
lar characteristics involving cleft palate, ID, and psycho-
motor retardation. The deletion described here reduces
the smallest region of overlap to 2,262 kb and suggests
that the absence of a kidney and the presence of clubbed
feet in the patient described by Natt and colleagues [34]
as well as congenital heart defects are not caused by the
absence of genes present in the overlapping region.
One microimbalance belonging to group IIb was inher-
ited from the healthy parent of patient P24. It is a 64 kb
heterozygous deletion affecting exons 9 to 13 of ATRNL1.
A 325 kb deletion adjacent to this gene, described by Stark
et al., implicates this gene in cognitive impairment, autism
and several dysmorphic features. ATRNL1 is involved in
the regulation of energy homeostasis by binding to mela-
nocortins [41,42]. The two patients have some common
characteristics (Table 3), especially autistic traits, skeletal
abnormalities, and ID. However, the presence of the dele-
tion in the healthy mother of patient 24 makes it difficult
to assess the clinical significance of this CNV. Therefore,
sequencing of ATRNL1 was performed but no point muta-
tion was found. This CNV can then be considered patho-
genic with an incomplete penetrance or simply classified
as benign. A study with a larger number of controls is
therefore required because only intronic deletions were
found in our control database (10 CNVs, all in intron 26).
Five CNVs were found in 42 probands with consanguin-
eous parents. This confirms previous studies that showed
the importance of microarrays in the identification of
causes of ID/DD in probands with consanguineous parents
[43]. These CNVs have a pick-up rate of 3.4% (5/149).
Three of them were new homozygous deletions: a deletion
of the PTPRD gene in patient P20 and the two other CNVs
characterizing two new phenotypes in patients P22 and
Table 3 A comparison between two patients with a heterozygous deletion of ATRNL1
Present case P24 Stark et al.
Cardiac problems at birth - Small muscular ventricular septal defect at birth but closed spontaneously
Poor suck & hypotonia first weeks of life - +
Prominent forehead Small +
Epicanthal folds - +
Arched eyebrows + +
Long eyelashes +
Eye problems - +
Small mouth - +
Small and squared ears - +
Upslanting palpebral fissures +
Flat pillar of the nose, wide nose + -
Fingers/toes abnormalities Short second toe 2/3 toe syndactyly
Skeletal abnormalities Syringomyelia Radioulnar synostosis
Delay Severe Moderate, no developmental regression
Walked at the age of 30 months 24 months
Ataxic gait + +
Others eczema
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is still unclear, they were considered potentially causative
because they followed a pattern of autosomal recessive in-
heritance. A search for other patients with similar pheno-
types is necessary to accurately classify these CNVs.
Additionally, we looked for the presence of parental
consanguinity suggestive of autosomal recessive disor-
ders. We therefore compared the estimated coefficient
of inbreeding to the coefficient deduced from the pedi-
gree of each family, and interestingly, we noticed the oc-
currence of significant deviations from theoritical values.
In 17/42 patient (40.4%), a higher degree of relationship
than shown by their pedigree was observed. This vari-
ation is due to multiple loops of consanguinity or multiple
generations of inbreeding observed within the Lebanese
community [44], which complicates the estimation of the
degree of relationship. These cases were marked for
further investigation with the aim of sequencing candidate
genes within the ROH regions.
Finally, we established an internal database for poly-
morphic CNVs to help further studies discriminate be-
tween rare polymorphisms and disease-associated variants
(data not shown).
Conclusions
In conclusion, this is the first Lebanese study on ID/DD
patients. It has provided supporting evidence that whole-
genome analysis is a powerful method for uncovering
chromosomal imbalances and genomic rearrangements,
regardless of consanguinity in the parents of patients and
despite the challenge presented by analyzing some CNVs.Methods
Ethical statement
This study was carried out with protocols approved by
the Institutional Review Board (IRB) on human experi-
mentation at Saint Joseph University.
Patients and controls from all regions of Lebanon were
recruited through the Medical Genetics Unit of Saint
Joseph University over a period of three years. Approval
for the study and informed written consent were obtained
from legally authorized patient representatives and the 99
healthy subjects.
Cohort
A total of 149 Lebanese children (88 boys and 61 girls) with
moderate to severe ID associated with developmental delay
and/or congenital abnormalities (CA) of unknown origin
were analyzed using the Affymetrix Cyto 2.7 M platform.
Known syndromes were eliminated using karyotyping,
subtelomere FISH, MLPA, and/or fragile X testing. Copy
number analysis was performed for 99 healthy Lebanese
individuals using two types of arrays, SNP 6.0 and Cyto 2.7.
Chromosomal microarray analysis-based technologies
Cyto 2.7M
Genomic DNA, isolated from peripheral blood samples
using the salting-out technique, was amplified, purified,
fragmented, denatured, and then hybridized into the Cyto
2.7 M, following the Affymetrix® standard protocol.
A single array has a high density of 2,361,876 non-
polymorphic markers and 400,103 SNP markers, with
whole-genome backbone coverage of ~1 kb spacing.
Choucair et al. Molecular Cytogenetics  (2015) 8:26 Page 7 of 9The analysis of scanned chips was performed using the
Affymetrix Chromosome Analysis Suite software (ChAS
v.1.0.1). The software initiates studies on arrays of which
the Median Absolute Pairwise Difference score (MAPD),
the waviness segment count, and the SNPQC meet the
Quality Control (QC) criteria set by the manufacturer:
MAPD < 0.27; SNPQC > 1.1; Wav Seg Count ≤ 30 [45].
The annotation file used in our analysis can be found on
the Affymetrix website, listed as ArrayNA30.1 (hg18).
SNP 6.0
This array consists of 906,600 SNP probes and 900,000
non-polymorphic oligonucleotides used for detecting
CNVs with an average spacing of 0.7 kb. The preparation
and hybridization of DNA samples were performed fol-
lowing the Affymetrix® 6.0 standard protocol.
Assessment of array parameters
Assessing the existence and causality of the small CNVs
identified by this high-resolution platform was very chal-
lenging and required the consideration of array parame-
ters. We selected ninety-nine random CNVs, with no
threshold, for validation by quantitative PCR (Q-PCR).
Our results (data not shown but available upon request)
prompted us to select a threshold of 62 kb with at least
49 consecutive markers, which we further utilized to
filter the CNV analysis results.
Detection of parental disomy and consanguinity
Large ROH observed on a single chromosome can be
suggestive of parental disomy (≥10 Mb); however, when
distributed throughout the genome, large ROHs are indi-
cative of a consanguineous relationship between the
patient’s parents. Small stretches of homozygosity < 3 Mb
were ignored because they are common even in outbred
populations [46].
To detect possible parental consanguinity, we com-
pared the patient’s ROH size, calculated on several chro-
mosomes (sum of ROH ≥ 3 Mb), with the theoretical
ROH size, estimated by multiplying the 2,867,732,772-
base total size of the autosomal haploid genome (NCBI
Build 36.1 assembly (2006)) by the theoretical value of
the coefficient of inbreeding [47]. We also defined a vari-
able range of expected ROH size by using the mid-line
between theoretical average sizes as used by Fan et al.
(Additional file 5: Table S4) [43].
Quantitative PCR (Q-PCR)
The array findings were confirmed and their de novo and
inherited status were distinguished using Q-PCR with an
ABI Prism 7500 system (Applied Biosystems, Foster City,
CA, USA) using fluorescent SYBR Green dye (ABI). Spe-
cific primers targeting genes or intronic sequences were
designed using Primer Express 3 Software (ABI).PCR was performed in a 20 μl reaction volume
containing 10 μl Power SYBR-Green PCR Master Mix
(ABI), 10 pmol forward and reverse primers, and 10 ng
of genomic DNA. The reaction cycling conditions were
95°C for 10 min, followed by 40 cycles of 95°C for 15 sec
and 60°C for 1 minute. Each sample was run in triplicate
for the quantification of the expression level of a target
gene and compared to the expression level of two
endogenous genes.
Data evaluation was carried out using the ABI Prism
Sequence Detection System (SDS) using the comparative
ΔΔ threshold cycle number (Ct) method. To exclude the
presence of non-specific products, a melting-curve ana-
lysis of the products was performed after completion of
the amplification.
Workflow for selecting CNVs
To assess the clinical significance of the detected CNVs,
we followed the recommended steps from Miller et al.
and Buysse et al. [10,47,48].
All imbalances found at least twice in the Database of
Genomic Variants (DGV) and our internal database of
healthy individuals were considered to be benign and
excluded from further analysis. CNVs under the selected
threshold, as well as those that did not involve genes or
miRNAs, were also excluded. The remaining CNVs were
classified into groups.
Group I contains pathogenic CNVs overlapping critical
regions of known microdeletions or microduplications
and/or involving genes already described as causing a
phenotype, especially ID. These CNVs are found in the
publicly available DECIPHER (http://decipher.sanger.ac.uk)
and ISCA (www.clinicalgenome.org) databases and in
published literature such as the Catalogue of Unbalanced
Chromosome Aberrations in Man [9].
Group II contains genomic imbalances classified as
being variants of uncertain clinical significance because of
their unclear possible pathogenicity. Parental studies were
mandatory for the classification of these CNVs. VOUS
were grouped into four categories: Group IIa contains
rare, likely pathogenic CNVs that mostly occur de novo
and includes genes with a possible correlation to the
phenotype (abnormal with a low recurrence risk); Group
IIb corresponds to CNVs for which clinical interpretation
remains uncertain, even after parental studies, owing to
variable expressivity or incomplete penetrance; Group IIc
includes all inherited CNVs, also called familial variants,
that were considered to be benign; and Group IId contains
VOUS that could not be further tested owing to the
absence of parental DNA.
DNA sequencing
The coding sequences of ATRNL1 were sequenced after
DNA amplification by PCR (NM-207303). Primers were
Choucair et al. Molecular Cytogenetics  (2015) 8:26 Page 8 of 9designed using Primer 3 (http://frodo.wi.mit.edu) and
OLIGOS v.9.3, and checked for specificity using BLAST
(http://www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi).
PCR reactions were performed using Taq DNA polymer-
ase (Invitrogen Life Technologies, Carlsbad, Calif., USA).
PCR products from genomic DNA were purified using the
illustra TM GFX PCR DNA and Gel Band Purification
Kit (GE Healthcare, Buckinghamshire, UK), and sequenced
using the BigDye _ Terminator v1.1 Cycle Sequencing
Kit (Applied Biosystems, Foster City, Calif., USA) under
standard conditions. The labeled products were sub-
jected to electrophoresis on an Applied Biosystems Genetic
Analyzer sequencing system.
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